Dear Editor,Great progress has been made in the clinical use of photodynamic therapy(PDT)for the treatment of patients with superficial tumors[1].However,cancer recurrence and metastasis have limited the application o...Dear Editor,Great progress has been made in the clinical use of photodynamic therapy(PDT)for the treatment of patients with superficial tumors[1].However,cancer recurrence and metastasis have limited the application of PDT in the treatment of solid tumors and advanced cancers.In this context,combining PDT with other complementary immunotherapy regimens may overcome these limitations of PDT[2].展开更多
基金Yang Hao received finacial support from the China Scholarship and Jilin Province Chinese Postdoctoral International Exchange Program(YJ20220406)Zili Gu,Zhenfeng Yu and Sen Ma received financial support from the China Scholarship Council,and Peter ten Dijke received funding from Cancer Genomics Centre NetherlandsTimo Schomann and Alireza Haghparast received funding from the European Commission,grants H2020-MSCA-RISE CANCER(777682)and H2020-WIDESPREAD-05-2017-Twinning SIMICA(852985).
文摘Dear Editor,Great progress has been made in the clinical use of photodynamic therapy(PDT)for the treatment of patients with superficial tumors[1].However,cancer recurrence and metastasis have limited the application of PDT in the treatment of solid tumors and advanced cancers.In this context,combining PDT with other complementary immunotherapy regimens may overcome these limitations of PDT[2].
